Guanine Inc

Guanine is building a universal electrochemical sensing layer for modern diagnostics. The company’s platform replaces fragmented diagnostic technologies—optical systems, PCR workflows, and single-analyte assays—with a single, scalable electrochemical architecture capable of high-plex, multi-omic measurement from a single sample. Guanine combines programmable electrochemical waveforms, magnetic sample concentration, and composite multiplex encoding to quantify proteins, metabolites, nucleic acids, and functional drug response rapidly and cost-effectively—without optics, thermal cycling, or complex instrumentation. The platform is designed to scale from point-of-care and hospital settings to OEM diagnostic systems and high-throughput laboratory formats. Initial clinical focus: sepsis. Guanine is developing an integrated sepsis diagnostic workflow that delivers:~20-minute host response profiling ~60-minute pathogen identification and antimicrobial resistance detection ~90-minute culture-free phenotyping This time-aligned approach is intended to provide actionable insight early in the clinical decision window, supporting more precise therapy selection and antimicrobial stewardship. Guanine is also building a high-plex, multi-omic electrochemical sensing layer for OEM diagnostics. OEM partners can deploy the platform to accelerate assay development, reduce system cost and complexity, and expand multiplexing across infectious disease, chronic diseases, pharmaceutical diagnostics, and precision health AI applications. Guanine is backed by deep electrochemical biosensing expertise, prior NASA biosensor commercialization, and an expanding portfolio of issued and pending patents. The company has a collaboration with Mount Sinai Health Systems and is actively engaging clinical partners, OEMs and investors to scale the platform globally.